keyword
MENU ▼
Read by QxMD icon Read
search

Painful diabetic polyneuropathy

keyword
https://www.readbyqxmd.com/read/28263010/bilateral-analgesic-effects-of-abobotulinumtoxina-dysport-%C3%A2-following-unilateral-administration-in-the-rat
#1
C Favre-Guilmard, P-E Chabrier, M Kalinichev
BACKGROUND: In addition to inhibition of muscle and glandular hyperactivity, botulinum neurotoxin (BoNT) type A also interferes with pain processing. Previously, in a rat model of paclitaxel-induced polyneuropathy, abobotulinumtoxinA (aboBoNT-A) elicited analgesic effects not only in the injected paw, but also in the contralateral, non-injected paw. METHODS: Here, we assessed bilateral analgesic effects of unilateral aboBoNT-A in several chronic pain models in Sprague-Dawley rats...
March 6, 2017: European Journal of Pain: EJP
https://www.readbyqxmd.com/read/28259159/measurement-properties-of-paindetect-rasch-analysis-of-responses-from-community-dwelling-adults-with-neuropathic-pain
#2
Tara L Packham, Joseph C Cappelleri, Alesia Sadosky, Joy C MacDermid, Florian Brunner
BACKGROUND: painDETECT (PD-Q) is a self-reported assessment of pain qualities developed as a screening tool for pain of neuropathic origin. Rasch analysis is a strategy for examining the measurement characteristics of a scale using a form of item response theory. We conducted a Rasch analysis to consider if the scoring and measurement properties of PD-Q would support its use as an outcome measure. METHODS: Rasch analysis was conducted on PD-Q scores drawn from a cross-sectional study of the burden and costs of NeP...
March 4, 2017: BMC Neurology
https://www.readbyqxmd.com/read/28252606/-diabetic-asymmetric-proximal-neuropathy
#3
S V Kotov, I G Rudakova, E V Isakova, Yu A Belova, T V Volchenkova, M Khirbek, G A Stashuk
AIM: To study the prevalence, clinical features and treatment of diabetic asymmetric proximal neuropathy (DAPN). MATERIAL AND METHODS: Four hundred and forty-five patients with diabetes mellitus (DM), 257 women and 188 men, mean age 47.6±0.5 years, including 163 patients with DM type I and 282 with DM type II, were examined. RESULTS AND CONCLUSION: Distal symmetric sensory motor polyneuropathy was found in 62% of the patients, autonomic neuropathy in 25...
2017: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://www.readbyqxmd.com/read/28057506/patient-perspectives-on-peripheral-neuropathic-pain-experience-within-the-community
#4
Devada Singh-Franco, Robin J Jacobs
Purpose of this cross-sectional study was to explore the relationship between neuropathic physical complaints (NPC) and quality-of-life (QoL) in community-dwelling patients with diabetes in Broward County, Florida. Adult patients were invited to complete a 10-minute paper questionnaire at a community hospital between October 2014-April 2016. Analysis of data from 124 participants (60 with distal symmetric polyneuropathy (DSPN) diagnosis versus 64 without DSPN diagnosis) with NPC, showed those with DSPN had a longer duration of diabetes, suffered a higher number of NPC, and had a lower QoL (all p≤0...
December 22, 2016: Diabetes & Metabolic Syndrome
https://www.readbyqxmd.com/read/28005560/capsaicin-8-patch-repeat-treatment-in-non-diabetic-peripheral-neuropathic-pain-a-52-week-open-label-single-arm-safety-study
#5
Rafael Gálvez, Marie-Louise Navez, Graeme Moyle, Christian Maihöfner, Malcolm Stoker, Etienne Ernault, Turo J Nurmikko, Nadine Attal
OBJECTIVES: To investigate long-term safety and tolerability of capsaicin 8% patch repeat treatment in non-diabetic patients with peripheral neuropathic pain (NP). METHODS: Prospective, open-label, observational study in patients with post-herpetic neuralgia, post-traumatic or post-surgical nerve injury, HIV-associated distal sensory polyneuropathy, or other peripheral NP, and average daily pain score ≥4, received ≤6 capsaicin 8% patch treatments over 52 weeks according to clinical need (retreatment at 9-12 wk intervals)...
December 21, 2016: Clinical Journal of Pain
https://www.readbyqxmd.com/read/27984834/-ophthalmological-monitoring-of-diabetic-neuropathy-in-a-mouse-model
#6
S Baltrusch
Patients with diabetes mellitus suffer from late damage, including microvascular and macrovascular complications and diabetic polyneuropathy, even though blood glucose is well controlled and the HbA1c value normalised. Peripheral nerves are affected, and when these are damaged, this can result in disturbed sensation and pain. Such nerves are mainly Aδ und C fibres, which are present in the skin, but also in the subbasal nerve plexus of the cornea. Imaging of the subbasal nerve plexus using microscopic techniques allows a very early and objective view of neuropathy, which is only possible invasively by skin biopsy...
December 2016: Klinische Monatsblätter Für Augenheilkunde
https://www.readbyqxmd.com/read/27891705/spinal-cord-stimulation-in-experimental-chronic-painful-diabetic-polyneuropathy-delayed-effect-of-high-frequency-stimulation
#7
M van Beek, M van Kleef, B Linderoth, S M J van Kuijk, W M Honig, E A Joosten
BACKGROUND: Spinal cord stimulation (SCS) has been shown to provide pain relief in painful diabetic polyneuropathy (PDPN). As the vasculature system plays a great role in the pathophysiology of PDPN, a potential beneficial side-effect of SCS is peripheral vasodilation, with high frequency (HF) SCS in particular. We hypothesize that HF-SCS (500 Hz), compared with conventional (CON) or low frequency (LF)-SCS will result in increased alleviation of mechanical hypersensitivity in chronic experimental PDPN...
November 28, 2016: European Journal of Pain: EJP
https://www.readbyqxmd.com/read/27813425/emerging-drugs-for-diabetic-peripheral-neuropathy-and-neuropathic-pain
#8
Nikolaos Papanas, Dan Ziegler
Diabetic sensorimotor polyneuropathy (DSPN) is a common complication of diabetes. Areas covered: In this review, the authors discuss the emerging drugs for DSPN, which aim either at improving alleviation of neuropathic pain or addressing the putative mechanisms underlying diabetic neuropathy. Expert Opinion: Current treatment does not address the sensory deficits and pathogenesis underlying DSPN, so there is an unmet need for treatment options targeting the natural history of the condition. Some of these pathogenetic therapies have demonstrated clinically relevant improvements in neuropathic endpoints in recent randomised controlled trials...
December 2016: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/27802497/association-between-metabolic-syndrome-components-and-polyneuropathy-in-an-obese-population
#9
Brian C Callaghan, Rong Xia, Evan Reynolds, Mousumi Banerjee, Amy E Rothberg, Charles F Burant, Emily Villegas-Umana, Rodica Pop-Busui, Eva L Feldman
Importance: Past studies have shown an association between metabolic syndrome and polyneuropathy, but the precise components that drive this association remain unclear. Objectives: To determine the prevalence of polyneuropathy stratified by glycemic status in well-characterized obese and lean participants and investigate the association of specific components of metabolic syndrome with polyneuropathy. Design, Setting, and Participants: We performed a cross-sectional, observational study from November 1, 2010, to December 31, 2014, in obese participants (body mass index [calculated as weight in kilograms divided by height in meters squared] of 35 or more with no comorbid conditions or 32 or more with at least 1 comorbid condition) from a weight management program and lean controls from a research website...
December 1, 2016: JAMA Neurology
https://www.readbyqxmd.com/read/27790622/an-occult-malignancy-behind-a-demyelinating-disease-poems-syndrome
#10
Saberio Lo Presti, Prashanth Kanagarajah, Daniela Pirela, Diana Morlote, Mike Cusnir
We report a case of a 38-year-old man presenting with bilateral lower extremity weakness and paresthesias that progressed during a 4-month period to severe polyneuropathy forcing the patient to be bed bound. Throughout his multiple hospitalizations, he was treated erroneously for chronic inflammatory demyelinating polyneuropathy, without significant improvement in his symptoms. In addition, he developed hepatosplenomegaly (organomegaly); endocrinopathies such as diabetes mellitus, central hypogonadism, and hypothyroidism; monoclonal spike evidenced in the serum electrophoresis; and hyperpigmentation of skin, altogether consistent with POEMS syndrome...
October 2016: Journal of Investigative Medicine High Impact Case Reports
https://www.readbyqxmd.com/read/27730378/diagnostic-value-of-blood-tests-for-occult-causes-of-initially-idiopathic-small-fiber-polyneuropathy
#11
Magdalena Lang, Roi Treister, Anne Louise Oaklander
Small-fiber polyneuropathy (SFPN) causes non-specific symptoms including chronic pain, cardiovascular, gastrointestinal, and sweating complaints. Diagnosis is made from history and exam in patients with known risk factors such as diabetes, but objective test confirmation is recommended for patients without known risks. If tests confirm SFPN, and it is "initially idiopathic" (iiSFPN), screening for occult causes is indicated. This study's aim was to evaluate the 21 widely available, recommended blood tests to identify the most cost-effective ones and to learn about occult causes of iiSFPN...
December 2016: Journal of Neurology
https://www.readbyqxmd.com/read/27637963/peripheral-neuropathies
#12
R Hanewinckel, M A Ikram, P A Van Doorn
Peripheral neuropathies are diseases of the peripheral nervous system that can be divided into mononeuropathies, multifocal neuropathies, and polyneuropathies. Symptoms usually include numbness and paresthesia. These symptoms are often accompanied by weakness and can be painful. Polyneuropathies can be divided into axonal and demyelinating forms, which is important for diagnostic reasons. Most peripheral neuropathies develop over months or years, but some are rapidly progressive. Some patients only suffer from mild, unilateral, slowly progressive tingling in the fingers due to median nerve compression in the wrist (carpal tunnel syndrome), while other patients can be tetraplegic, with respiratory insufficiency within 1-2 days due to Guillain-Barré syndrome...
2016: Handbook of Clinical Neurology
https://www.readbyqxmd.com/read/27592367/physical-activity-and-albuminuria-were-associated-with-painful-diabetic-polyneuropathy-in-type-2-diabetes-in-an-ethnic-chinese-population
#13
Sheng-Shu Chiang, Chia-Lin Lee, Hsiu-Chen Liu, Jun-Sing Wang, I-Te Lee, Yuh-Min Song, Chia-Po Fu, Yu-Fen Li, Wayne H-H Sheu, Shih-Yi Lin
BACKGROUND: Diabetic neuropathy is a common complication in patients with type 2 diabetes. However, the prevalence of painful diabetic polyneuropathy (PDPN) have been less studied. We examined the prevalence and risk factors of PDPN in outpatients with type 2 diabetes in an ethnic Chinese population. METHODS: This retrospective study enrolled 2358 outpatients with type 2 diabetes who had completed the Douleur Neuropathique en 4 Questions (DN4) questionnaire from January 2013 to October 2013...
November 1, 2016: Clinica Chimica Acta; International Journal of Clinical Chemistry
https://www.readbyqxmd.com/read/27584552/peripheral-neuropathy-in-mouse-models-of-diabetes
#14
REVIEW
Corinne G Jolivalt, Katie E Frizzi, Lucie Guernsey, Alex Marquez, Joseline Ochoa, Maria Rodriguez, Nigel A Calcutt
Peripheral neuropathy is a frequent complication of chronic diabetes that most commonly presents as a distal degenerative polyneuropathy with sensory loss. Around 20% to 30% of such patients may also experience neuropathic pain. The underlying pathogenic mechanisms are uncertain, and therapeutic options are limited. Rodent models of diabetes have been used for more than 40 years to study neuropathy and evaluate potential therapies. For much of this period, streptozotocin-diabetic rats were the model of choice...
September 1, 2016: Current Protocols in Mouse Biology
https://www.readbyqxmd.com/read/27417167/activity-for-diabetic-polyneuropathy-adapt-study-design-and-protocol-for-a-2-site-randomized-controlled-trial
#15
Patricia M Kluding, J Robinson Singleton, Mamatha Pasnoor, Mazen M Dimachkie, Richard J Barohn, A Gordon Smith, Robin L Marcus
BACKGROUND: Half of all patients with diabetes develop diabetic peripheral neuropathy (DPN), a complication leading to reduced mobility and quality of life. Although there are no proven pharmacologic approaches to reduce DPN risk or slow its progression, evidence suggests that physical activity may improve symptoms and enhance peripheral nerve regeneration. OBJECTIVE: The aim of the study will be to determine the impact of an intense lifestyle intervention on neuropathy progression and quality of life in individuals with DPN...
July 14, 2016: Physical Therapy
https://www.readbyqxmd.com/read/27337438/independent-risk-factors-for-positive-and-negative-symptoms-in-patients-with-diabetic-polyneuropathy
#16
Reo Inoue, Masahiko Sumitani, Tetsuyuki Yasuda, Mayumi Tsuji, Masaya Nakamura, Iichiro Shimomura, Masahiko Shibata, Yoshitsugu Yamada
Patients with diabetes occasionally develop diabetic polyneuropathy (DPN), which is characterized by both positive symptoms such as pain and negative symptoms such as numbness/dysesthesia. However, these symptoms have always been collectively analyzed to determine their risk factors. This study aimed to independently analyze the risk factors for neuropathic pain and numbness/dysesthesia in DPN patients. In total, 298 patients with diabetes (age: 61.1 ± 10.4 years; 176 male) were included. The relationships among the incidence of DPN and its clinical parameters were determined using logistic regression models...
September 2016: Journal of Pain & Palliative Care Pharmacotherapy
https://www.readbyqxmd.com/read/27334483/diabetic-peripheral-neuropathic-pain-is-a-stronger-predictor-of-depression-than-other-diabetic-complications-and-comorbidities
#17
Cinzia D'Amato, Roberto Morganti, Carla Greco, Federica Di Gennaro, Laura Cacciotti, Susanna Longo, Giorgia Mataluni, Davide Lauro, Girolama A Marfia, Vincenza Spallone
AIMS: To investigate the independent effect on depression of painless diabetic polyneuropathy, painful diabetic polyneuropathy, and general and diabetes-related comorbidities. METHODS: In 181 patients, the presence of painless diabetic polyneuropathy, painful diabetic polyneuropathy, comorbidities and depression was assessed using the Michigan Neuropathy Screening Instrument Questionnaire, the Michigan Diabetic Neuropathy Score, nerve conduction studies, the Douleur Neuropathique en 4 Questions, the Charlson Comorbidity Index and the Beck Depression Inventory-II...
November 2016: Diabetes & Vascular Disease Research
https://www.readbyqxmd.com/read/27322439/a-standardized-clinical-evaluation-of-phenotypic-diversity-in-diabetic-polyneuropathy
#18
Joachim Scholz, James P Rathmell, William S David, David A Chad, Alithia C Broderick, Stephen G Perros, Naomi S Shin, Jenna L Wells, John B Davis, Charles J DiMaggio, Shuang Wang, Simon N Tate
Diabetic polyneuropathy (DPN) is a major cause of neuropathic pain and a frequent target condition in analgesic treatment trials. Differences in the clinical symptoms and signs associated with DPN suggest distinct pathophysiological mechanisms underlying nerve damage and dysfunction that are likely to have therapeutic relevance. The aim of this study was to develop a tool for the bedside assessment of painful neuropathies such as DPN that captures the diversity of phenotypes. Sixty-one patients with type 2 diabetes and painful neuropathy, 19 patients with painless DPN, 25 patients with type 2 diabetes but no clinical evidence of neuropathy, and 20 healthy control subjects completed a structured interview (47 items) and a standardized physical examination (39 items)...
October 2016: Pain
https://www.readbyqxmd.com/read/27212074/high-plasma-pentraxin-3-levels-in-diabetic-polyneuropathy-patients-with-nociceptive-pain
#19
Celal Salcini, Belkis Atasever-Arslan, Gulin Sunter, Hazal Gur, Fatma Busra Isik, Cemil Can Saylan, Ayse Destina Yalcin
Diabetic polyneuropathy is the most common neurologic complication of diabetes mellitus. Underlying mechanisms of diabetic polyneuropathy are related to various metabolic and inflammatory pathways. Pentraxin 3 (PTX3) is an acute phase protein that is produced locally at the inflammatory sites by several cell types. Thioredoxin binding protein 2 (TBP2) is a thioredoxin regulator involved in intracellular energy pathways and cell growth. We measured the plasma levels of PTX3 and TBP2 in type 2 diabetic patients (n = 27) with pain complaints and compared their levels with those of healthy age- and sex-matched subjects (n = 24)...
2016: Tohoku Journal of Experimental Medicine
https://www.readbyqxmd.com/read/27162603/could-spinal-canal-compression-be-a-cause-of-polyneuropathy
#20
Richard Bostelmann, Samis Zella, Hans Jakob Steiger, Athanasios K Petridis
Causality between spinal cord compression and polyneuropathy is difficult to define, especially under the circumstances that polyneuropathy can have many causes. Seven patients with spinal cord compression and electrophysiological signs of polyneuropathy were treated surgically on decompression of their spinal canal stenosis in the time from April 2010 to January 2013. Median follow up time was 9 months (2-23 months). Causes of polyneuropathy were: 1 patient with methotrexate-induced polyneuropathy, 1 endocrine-dysfunction-induced, 2 with diabetic-polyneuropathy, and 3 patients had unknown reasons...
March 25, 2016: Clinics and Practice
keyword
keyword
69247
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"